Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Towards a more generalizable genomic risk classification for acute myeloid leukemia (AML)

Award Number: R01CA284595
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/18/2023
PERIOD OF PERFORMANCE END DATE: 07/31/2028

Group Awards By:

View Award Description

Towards a more generalizable genomic risk classification for acute myeloid leukemia (AML) - Acute myeloid leukemia (AML) is the most common adult acute leukemia. Molecular features such as cytogenetics and somatic mutations are essential components of risk stratification; used in daily clinical practice to determine treatment modality and intensity. Our knowledge of recurrent genetic AML-associated features, survival associations, subsequent genetic risk classification and clinical practice is informed by large-scale genomic studies performed over the past decade. Current clinical practice is predicated on the supposition that adequate testing has been performed and that genetic background should not interplay with the known AML-associated genetic and genomic landscape or with genes that associate with treatment response and/or that drive AML-genesis. However, our published and preliminary data reveal that constitutional genetic elements affect not only the frequencies and impact of known AML-associated gene mutations, but also multiple recurrent variants in genes thus-far not implicated in AML-genesis. We hypothesize that: a) known AML-associated drivers may carry different prognostic significance and might need to be adjusted in clinical risk classifications depending on genetic backgrounds, and b) some unrecognized molecular features are novel drivers of AML-genesis and/or therapy resistance. We propose to extend our initial studies of AML genomes and genomics to provide statistical confidence around frequently mutated genes, and a more precise, molecularly-adjusted risk and treatment stratification for AML patients. Next, we will focus on NPM1c, a genotype which currently is predicted to confer favorable outcome in AML patients. We will use cutting-edge single-cell multiomic assays to delineate bystander clonal mutations from potential driver mutations, then we will biologically test their roles in clonality/leukemia-stem-cell frequency and treatment response in genetically heterogeneous patients. We predict this approach to provide an improved characterization of the genetic and genomic landscape of AML, identify those variants with prognostic significance, and provide exemplars of heretofore unrecognized drivers of treatment response and survival. The overall goal is to enable precision oncology approaches which accommodate the effects of underlying human genetics in all patients.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $648,220 )
2026	2026	OHIO STATE UNIVERSITY, THE	1960 KENNY RD	COLUMBUS	OH	43210	FRANKLIN	USA	Cancer Cause and Prevention Research	001	4	8/31/2026	NON-COMPETING CONTINUATION	$648,220
2026	2025	OHIO STATE UNIVERSITY, THE	1960 KENNY RD	COLUMBUS	OH	43210	FRANKLIN	USA	Cancer Cause and Prevention Research	000	3	8/20/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $648,220

Issue Date FY: 2025 ( Subtotal = $652,141 )
2025	2025	OHIO STATE UNIVERSITY, THE	1960 KENNY RD	COLUMBUS	OH	43210	FRANKLIN	USA	Cancer Cause and Prevention Research	001	3	8/4/2025	NON-COMPETING CONTINUATION	$652,141
2025	2024	OHIO STATE UNIVERSITY, THE	1960 KENNY RD	COLUMBUS	OH	43210	FRANKLIN	USA	Cancer Cause and Prevention Research	000	2	4/8/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $652,141

Issue Date FY: 2024 ( Subtotal = $622,018 )
2024	2024	OHIO STATE UNIVERSITY, THE	1960 KENNY RD	COLUMBUS	OH	43210	FRANKLIN	USA	Cancer Cause and Prevention Research	000	2	8/8/2024	NON-COMPETING CONTINUATION	$622,018
														Subtotal = $622,018

Issue Date FY: 2023 ( Subtotal = $687,428 )
2023	2023	OHIO STATE UNIVERSITY, THE	1960 KENNY RD	COLUMBUS	OH	43210	FRANKLIN	USA	Cancer Cause and Prevention Research	000	1	9/18/2023	NEW	$687,428
														Subtotal = $687,428

Grand Total All Awards = $2,609,807

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Towards a more generalizable genomic risk classification for acute myeloid leukemia (AML)

Award Number: R01CA284595

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/18/2023

PERIOD OF PERFORMANCE END DATE: 07/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer